French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia

Launched by UNIVERSITY HOSPITAL, TOULOUSE · Aug 18, 2016

Keywords

ClinConnect Summary

The CARMEN trial is a national study in France that looks at adults who have recently been diagnosed with two blood disorders: Immune Thrombocytopenia (ITP) and Autoimmune Hemolytic Anemia (AIHA). The goal of this registry is to gather real-world information about these conditions, including how they affect patients and how well different treatments work in practice. The researchers want to understand the benefits and risks of the treatments patients receive, as well as how closely doctors follow the recommended guidelines for managing these diseases.

To participate in this trial, individuals need to be at least 18 years old and must have been newly diagnosed with ITP or AIHA, or they may be starting a specific treatment called FOSFAMATINIB. Importantly, participants should be willing to allow their health data to be collected for the study. Those who join can expect their experiences and treatment outcomes to contribute valuable insights that may help improve care for future patients with these conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • adult patients (18+ year-old)
• • newly diagnosed for ITP/AIHA or initiation of FOSFAMATINIB
• Exclusion criteria:
• • - opposition to data collection